Single- and Multiple- Dose-Escalation Study to Investigate the Safety and Tolerability of T89 in Japanese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2014
Price : $35 *
At a glance
- Drugs T 89 (Primary)
- Indications Angina pectoris
- Focus Adverse reactions
- Sponsors Tasly Pharmaceuticals, Inc.
- 28 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Sep 2012 New trial record